source
- Priavoid's Alzheimer's pill PRI-002 fails Phase 2 trialGerman biotech startup Priavoid has been developing a small-molecule pill intended to break up amyloid protein clumps in the brains of Alzheimer's patients. The company recently reported results f…
- Mount Sinai researchers map enzyme structure linked to rare metabolic disorder GA1Researchers at Icahn School of Medicine at Mount Sinai have determined the crystal structure of an upstream enzyme involved in glutaric aciduria type 1 (GA1), a rare neuro‑metabolic disease. GA1 r…